Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 3/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2361668 | 0.74 | EGFR (0.44) | EGFR | |
| SCHEMBL367523 | 0.67 | EGFR (0.32) | EGFR | |
| SCHEMBL14989378 | 0.67 | — | — | |
| SCHEMBL9422646 | 0.65 | — | — | |
| SCHEMBL6770447 | 0.64 | — | — | |
| SCHEMBL6235782 | 0.61 | — | — | |
| SCHEMBL7057830 | 0.61 | — | — | |
| SCHEMBL7657126 | 0.61 | CYP2A6 (0.32) | — | |
| SCHEMBL11250455 | 0.61 | — | — | |
| SCHEMBL4268549 | 0.60 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2021216754-A1 | USE OF P38 MAPK INHIBITORS FOR PREVENTION AND TREATMENT OF AGING AND AGING-RELATED DISORDERS AND FOR BOOSTING AN IMMUNE SYSTEM | Spring Discovery, Inc. (US) | 2021-10-28 | — | — | WO | claimed |
| EP-1755607-A2 | COMPOSITIONS AND TREATMENTS FOR INHIBITING KINASE AND/OR HMG-COA REDUCTASE | Pharmix Corporation (US) | 2007-02-28 | — | — | EP | claimed |
| WO-2006028524-A2 | COMPOSITIONS AND TREATMENTS FOR INHIBITING KINASE AND/OR HMG-COA REDUCTASE | PHARMIX CORPORATION (US) | 2006-03-16 | — | — | WO | claimed |
| US-20050272770-A1 | Compositions and treatments for inhibiting kinase and/or HMG-CoA reductase | NUMERATE, INC. | 2005-12-08 | — | — | US | claimed |
| US-20050025765-A1 | Trans-capsular administration of high specificity cytokine inhibitors into orthopedic joints | DEPUY SPINE, INC. (US) | 2005-02-03 | — | — | US | claimed |
| WO-2021216754-A1 | USE OF P38 MAPK INHIBITORS FOR PREVENTION AND TREATMENT OF AGING AND AGING-RELATED DISORDERS AND FOR BOOSTING AN IMMUNE SYSTEM | Spring Discovery, Inc. (US) | 2021-10-28 | — | — | WO | disclosed |
| US-20140296216-A1 | PYRIMIDO[4,5-D]PYRIMIDINYL COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | GUANGZHOU INSTITUTE OF BIOMEDICINE AND HEALTH, CHINESE ACADEMY OF SCIENCES (CN) | 2014-10-02 | — | — | US | disclosed |
| US-7700768-B2 | Compounds | GLAXOSMITHKLINE LLC (US) | 2010-04-20 | — | — | US | disclosed |
| US-7629462-B2 | Tetrasubstituted pyrimidine compounds as chemical intermediates | SMITHKLINE BEECHAM CORPORATION (US) | 2009-12-08 | — | — | US | disclosed |
| US-20090048442-A1 | Novel compounds | SMITHKLINE BEECHAM CORPORATION | 2009-02-19 | — | — | US | disclosed |
| US-20080021054-A1 | COMPOSITIONS AND TREATMENTS FOR INHIBITING KINASE AND/OR HMG-COA REDUCTASE | NUMERATE, INC. | 2008-01-24 | — | — | US | disclosed |
| US-20070238743-A1 | 1,5-DISUBSTITUTED-3,4-DIHYDRO-1H-PYRIMIDO[4,5-D]PYRIMIDIN-2-ONE COMPOUNDS AND THEIR USE IN TREATING CSBP/P38 KINASE MEDIATED DISEASES | SMITHKLINE BEECHAM CORPORATION | 2007-10-11 | — | — | US | disclosed |
| US-20070004758-A1 | COMPOSITIONS AND TREATMENTS FOR INHIBITING KINASE AND/OR HMG-COA REDUCTASE | NUMERATE, INC. | 2007-01-04 | — | — | US | disclosed |
| US-20060084695-A1 | Compositions and treatments for inhibiting kinase and/or HMG-CoA reductase | NUMERATE, INC. | 2006-04-20 | — | — | US | disclosed |
| WO-2006028524-A2 | COMPOSITIONS AND TREATMENTS FOR INHIBITING KINASE AND/OR HMG-COA REDUCTASE | PHARMIX CORPORATION (US) | 2006-03-16 | — | — | WO | disclosed |
| US-20050288306-A1 | Compositions and treatments for inhibiting kinase and/or HMG-CoA reductase | NUMERATE, INC. | 2005-12-29 | — | — | US | disclosed |
| US-20050282883-A1 | Compositions and treatments for inhibiting kinase and/or HMG-CoA reductase | NUMERATE, INC. | 2005-12-22 | — | — | US | disclosed |
| US-20050277653-A1 | Compositions and treatments for inhibiting kinase and/or HMG-CoA reductase | NUMERATE, INC. | 2005-12-15 | — | — | US | disclosed |
| US-20050272770-A1 | Compositions and treatments for inhibiting kinase and/or HMG-CoA reductase | NUMERATE, INC. | 2005-12-08 | — | — | US | disclosed |
| US-20050261354-A1 | Compositions and treatments for inhibiting kinase and/or HMG-CoA reductase | NUMERATE, INC. | 2005-11-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050288306-A1 | Compositions and treatments for inhibiting kinase and/or HMG-CoA reductase | HMGCR, HMGB3, HMGB2 | EGFR 2315/4885 |
| US-20050282883-A1 | Compositions and treatments for inhibiting kinase and/or HMG-CoA reductase | HMGCR, HMGB3, HMGB2 | EGFR 2401/4885 |
| US-20060084695-A1 | Compositions and treatments for inhibiting kinase and/or HMG-CoA reductase | HMGCR, HMGB3, HMGB2 | EGFR 2315/4885 |
| US-20050277653-A1 | Compositions and treatments for inhibiting kinase and/or HMG-CoA reductase | HMGCR, HMGB3, HMGB2 | EGFR 2315/4885 |
| US-20140296216-A1 | PYRIMIDO[4,5-D]PYRIMIDINYL COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | EGFR, ERBB2, ERBB4 | EGFR 1/4885 |
| US-20070004758-A1 | COMPOSITIONS AND TREATMENTS FOR INHIBITING KINASE AND/OR HMG-COA REDUCTASE | HMGCR, HMGB3, HMGB2 | EGFR 2315/4885 |
| US-20070238743-A1 | 1,5-DISUBSTITUTED-3,4-DIHYDRO-1H-PYRIMIDO[4,5-D]PYRIMIDIN-2-ONE COMPOUNDS AND THEIR USE IN TREATING CSBP/P38 KINASE MEDIATED DISEASES | MAPKAPK2, CREBBP, CNBP | EGFR 3671/4885 |
| US-20050261354-A1 | Compositions and treatments for inhibiting kinase and/or HMG-CoA reductase | HMGCR, HMGB3, HMGB2 | EGFR 2315/4885 |
| US-20080021054-A1 | COMPOSITIONS AND TREATMENTS FOR INHIBITING KINASE AND/OR HMG-COA REDUCTASE | HMGCR, HMGB3, HMGB2 | EGFR 2315/4885 |
| US-20090048442-A1 | Novel compounds | CREBBP, MAPKAPK2, CNBP | EGFR 2738/4885 |
| US-20050272770-A1 | Compositions and treatments for inhibiting kinase and/or HMG-CoA reductase | HMGCR, HMGB3, HMGB2 | EGFR 2315/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.